Cardinal Health Reports Fiscal 2013 Third-Quarter Results and Raises Quarterly Dividend by 10 Percent

-- Non-GAAP diluted earnings per share (EPS) from continuing operations increases 28 percent to $1.201

-- Non-GAAP operating earnings increase 11% to $579 million

-- Fiscal 2013 non-GAAP earnings per share guidance raised to $3.67 - $3.71, which reflects an $0.18 EPS tax benefit from a third-quarter tax settlement

May 02, 2013, 07:00 ET from Cardinal Health

DUBLIN, Ohio, May 2, 2013 /PRNewswire/ -- Cardinal Health today reported fiscal year 2013 third-quarter revenue of $24.6 billion and a 28 percent increase in non-GAAP diluted earnings per share from continuing operations to $1.20. The earnings increase was driven by strong non-GAAP operating earnings growth and a tax settlement, which contributed $0.18 per share. On a GAAP basis, diluted EPS from continuing operations increased 5 percent to $1.00. Non-GAAP operating earnings of $579 million increased 11 percent, while operating earnings on a GAAP basis were down 10 percent to $475 million.

The company raised its fiscal 2013 outlook for non-GAAP diluted EPS from continuing operations to $3.67 to $3.71. The revised range includes the $0.18 tax settlement previously mentioned.

Cardinal Health also announced that its board of directors approved a 10 percent increase in the company's quarterly dividend to $0.3025 per share, or $1.21 per share on an annualized basis. The quarterly dividend is payable on July 15, 2013 to shareholders of record at close of business on July 1, 2013.

"We delivered another solid performance in our fiscal third quarter," said George Barrett, chairman and chief executive officer of Cardinal Health. "Both our Pharmaceutical and Medical segments reported double-digit profit growth. Our organization is successfully innovating and adapting our business lines and portfolio to an evolving market, with a focus on establishing a strategic edge in areas of higher growth. This was highlighted during the quarter with the acquisition of AssuraMed which will enable us to follow the care of patients to the home."  

Q3 FY13 SUMMARY


Q3 FY13

Q3 FY12

Y/Y

Revenue

$24.6 billion

$26.9 billion

(9%)





 

Operating Earnings

 

$475 million

 

$527 million

 

(10%)

Non-GAAP Operating Earnings

 

$579 million

 

$524 million

 

11%





Earnings from Continuing Operations

 

$346 million

 

$332 million

 

4%

Non-GAAP Earnings from Continuing Operations

 

$412 million

 

$327 million

 

26%





Diluted EPS from Continuing Operations

 

$1.00

 

$0.95

 

5%

Non-GAAP Diluted EPS from Continuing Operations

 

$1.20

 

$0.94

 

28%

Revaluation of the deferred tax liability as a result of an agreement with tax authorities positively impacted third-quarter fiscal 2013 GAAP and non-GAAP earnings from continuing operations by $64 million and GAAP and non-GAAP diluted EPS by $0.18 per share.

In the third quarter of fiscal 2012, a reduction in the fair value of the P4 Healthcare acquisition earn-out liability had positively impacted GAAP operating earnings by $55 million and GAAP diluted EPS by $0.10 per share.

SEGMENT RESULTS

Pharmaceutical segment

Revenue for the Pharmaceutical segment decreased 10 percent to $22.1 billion driven by the non-renewal of the Express Scripts contract and brand-to-generic conversions, partially offset by revenues from new customers. Segment profit increased 12 percent to $498 million as the company continued to benefit from a focus on product and customer mix and reflected strong performance from generics programs.


Q3 FY13

Q3 FY12

Y/Y

Revenue

$22.1 billion

$24.5 billion

(10%)

Segment Profit

$498 million

$446 million

12%

Medical segment

Revenue for the Medical segment increased 3 percent to $2.5 billion, driven by acquisitions, partially offset by one fewer sales day. Segment profit increased 12 percent to $100 million driven by the favorable impact of commodities and the performance of the preferred product portfolio. The increase was partially offset by rate compression, driven in part by customer mix.  Results were also moderated by softness in procedural-based utilization.


Q3 FY13

Q3 FY12

Y/Y

Revenue

$2.5 billion

$2.4 billion

3%

Segment Profit

$100 million

$89 million

12%

ADDITIONAL THIRD-QUARTER AND RECENT HIGHLIGHTS

  • Completed acquisition of AssuraMed, a leading direct-to-home medical supplies distributor
  • Named one of the National Association of Female Executives Top 50 companies for 2013
  • Launched the fourth in a series of Cardinal Health Foundation interactive Generation Rx toolkits, which are designed to help reduce the abuse of prescription drugs

CONFERENCE CALL

Cardinal Health will host a webcast and conference call today at 8:30 a.m. Eastern to discuss third-quarter results. To access the call and corresponding slide presentation, go to the Investors page at cardinalhealth.com. The call also can be accessed by dialing 877.870.9220 or 631.291.4512.

There is no pre-registration for the call; however, participants are advised to dial into the call at least 10 minutes prior to the start time.

Presentation slides and an audio replay will be archived on the website after the conclusion of the meeting. The audio replay will be available until June 1 by dialing 855.859.2056 or 404.537.3406, using passcode 35177390.

UPCOMING WEBCAST EVENTS

  • Bank of America Merrill Lynch 2013 Health Care Conference at 8:40 a.m. local time on May 14 in Las Vegas
  • Goldman Sachs 34th Annual Global Healthcare Conference at 8:40 a.m. local time on June 11 in Rancho Palos Verdes, Calif.

At these events, Cardinal Health will discuss the company's diverse products and services, company performance and strategies for continued growth. To access more details and live webcasts of these events, go to the Investors page at cardinalhealth.com. 

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $108 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while  reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #21 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at cardinalhealth.com and @CardinalHealth on Twitter.

1 See the attached tables for definitions of the non-GAAP financial measures presented in this news release and reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, analyst presentations and financial information regarding Cardinal Health is routinely posted and accessible on the Investors page at cardinalhealth.com.

Cautions Concerning Forward-Looking Statements This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; uncertainties relating to the ability of Cardinal Health to successfully mitigate the impact of the expiration of the pharmaceutical distribution contract with Walgreen Co. at the end of August 2013; the ability to achieve the expected benefits from the AssuraMed acquisition, including the expected accretion in non-GAAP earnings; the timing of generic and branded pharmaceutical introductions and the frequency or rate of pharmaceutical price appreciation or deflation; the non-renewal, early termination or a default under one or more key customer or supplier arrangements or changes to the terms of or level of purchases under those arrangements; uncertainties due to government health care reform including federal health care reform legislation; changes in the distribution patterns or reimbursement rates for health care products and services; and the effects of any investigation or action by any regulatory authority; changes in the cost of commodities such as oil-based resins, cotton, latex and diesel fuel. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of May 2, 2013. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.

 

Schedule 1

Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Statements of Earnings (Unaudited)

Third Quarter

(in millions, except per Common Share amounts)

2013

2012

% Change

Revenue

$

24,552

$

26,918

(9)

%

Cost of products sold

23,261

25,711

(10)

%

Gross margin

1,291

1,207

7

%

Operating expenses:

Distribution, selling, general and administrative expenses

712

683

4

%

Restructuring and employee severance

33

7

N.M.

Acquisition-related costs

53

(27)

N.M.

Impairments and loss on disposal of assets

21

17

N.M.

Litigation (recoveries)/charges, net

(3)

N.M.

Operating earnings

475

527

(10)

%

Other income, net

(6)

(7)

N.M.

Interest expense, net

34

24

42

%

Earnings before income taxes and discontinued operations

447

510

(12)

%

Provision for income taxes

101

178

(43)

%

Earnings from continuing operations

346

332

4

%

Earnings/(loss) from discontinued operations, net of tax

(1)

1

N.M.

Net earnings

$

345

$

333

4

%

Basic earnings per Common Share:

Continuing operations

$

1.01

$

0.96

5

%

Discontinued operations

N.M.

Net basic earnings per Common Share

$

1.01

$

0.96

5

%

Diluted earnings per Common Share:

Continuing operations

$

1.00

$

0.95

5

%

Discontinued operations

N.M.

Net diluted earnings per Common Share

$

1.00

$

0.95

5

%

Weighted-average number of Common Shares outstanding:

Basic

341

345

Diluted

345

349

 

Schedule 2

Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Statements of Earnings (Unaudited)

Year-to-Date

(in millions, except per Common Share amounts)

2013

2012

% Change

Revenue

$

75,673

$

80,788

(6)

%

Cost of products sold

72,000

77,383

(7)

%

Gross margin

3,673

3,405

8

%

Operating expenses:

Distribution, selling, general and administrative expenses

2,099

1,966

7

%

Restructuring and employee severance

39

12

N.M.

Acquisition-related costs

106

23

N.M.

Impairments and loss on disposal of assets

27

19

N.M.

Litigation (recoveries)/charges, net

(37)

(3)

N.M.

Operating earnings

1,439

1,388

4

%

Other income, net

(17)

(3)

N.M.

Interest expense, net

87

70

24

%

Earnings before income taxes and discontinued operations

1,369

1,321

4

%

Provision for income taxes

448

487

(8)

%

Earnings from continuing operations

921

834

10

%

Loss from discontinued operations, net of tax

(1)

(2)

N.M.

Net earnings

$

920

$

832

11

%

Basic earnings/(loss) per Common Share:

Continuing operations

$

2.70

$

2.42

12

%

Discontinued operations

(0.01)

N.M.

Net basic earnings per Common Share

$

2.70

$

2.41

12

%

Diluted earnings/(loss) per Common Share:

Continuing operations

$

2.68

$

2.39

12

%

Discontinued operations

(0.01)

(0.01)

N.M.

Net diluted earnings per Common Share

$

2.67

$

2.38

12

%

Weighted-average number of Common Shares outstanding:

Basic

341

345

Diluted

344

349

 

Schedule 3

Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets

(in millions)

March 31, 2013

June 30, 2012

(Unaudited)

Assets

Current assets:

Cash and equivalents

$

2,305

$

2,274

Trade receivables, net

6,416

6,355

Inventories

8,328

7,864

Prepaid expenses and other

878

1,017

Total current assets

17,927

17,510

Property and equipment, net

1,470

1,551

Goodwill and other intangibles, net

6,413

4,392

Other assets

913

807

Total assets

$

26,723

$

24,260

Liabilities and Shareholders' Equity

Current liabilities:

Accounts payable

$

12,049

$

11,726

Current portion of long-term obligations and other short-term borrowings

446

476

Other accrued liabilities

1,979

1,972

Total current liabilities

14,474

14,174

Long-term obligations, less current portion

3,714

2,418

Deferred income taxes and other liabilities

1,705

1,424

Total shareholders' equity

6,830

6,244

Total liabilities and shareholders' equity

$

26,723

$

24,260

 

Schedule 4

Cardinal Health, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited)

Third Quarter

Year-to-Date

(in millions)

2013

2012

2013

2012

Cash flows from operating activities:

Net earnings

$

345

$

333

$

920

$

832

(Earnings)/loss from discontinued operations, net of tax

1

(1)

1

2

Earnings from continuing operations

346

332

921

834

Adjustments to reconcile earnings from continuing operations to net cash provided by operating activities:

Depreciation and amortization

99

83

275

239

Impairments and loss on disposal of assets

21

17

27

19

Share-based compensation

22

22

68

63

Provision for bad debts

9

5

18

7

Change in fair value of contingent consideration obligation

(53)

(53)

Change in operating assets and liabilities, net of effects from acquisitions:

Decrease/(increase) in trade receivables

(147)

(478)

81

(310)

Decrease/(increase) in inventories

193

683

(343)

(870)

Increase in accounts payable

183

95

214

1,212

Other accrued liabilities and operating items, net

263

187

166

142

Net cash provided by operating activities

989

893

1,427

1,283

Cash flows from investing activities:

Acquisition of subsidiaries, net of cash acquired

(2,093)

(135)

(2,219)

(143)

Additions to property and equipment

(41)

(58)

(103)

(158)

Proceeds from maturities of held-to-maturity securities

11

71

46

Purchase of other investments

(6)

(6)

(11)

Net cash used in investing activities

(2,140)

(182)

(2,257)

(266)

Cash flows from financing activities:

Net change in short-term borrowings

(28)

4

(11)

8

Reduction of long-term obligations

(44)

(6)

(45)

Proceeds from long-term obligations, net of issuance costs

1,286

1,286

Net proceeds from issuance of Common Shares

37

12

63

23

Tax proceeds/(disbursements) from share-based compensation

(1)

3

(13)

3

Dividends on Common Shares

(93)

(74)

(258)

(226)

Purchase of treasury shares

(200)

(300)

Net cash provided by/(used in) financing activities

1,201

(99)

861

(537)

Net increase in cash and equivalents

50

612

31

480

Cash and equivalents at beginning of period

2,255

1,798

2,274

1,930

Cash and equivalents at end of period

$

2,305

$

2,410

$

2,305

$

2,410

 

Schedule 5

Cardinal Health, Inc. and Subsidiaries Total Company Business Analysis

Non-GAAP

Third Quarter

Third Quarter

(in millions)

2013

2012

2013

2012

Revenue

Amount

$

24,552

$

26,918

Growth rate

(9)%

3%

Operating earnings

Amount

$

475

$

527

$

579

$

524

Growth rate

(10)%

18%

11%

6%

Earnings from continuing operations

Amount

$

346

$

332

$

412

$

327

Growth rate

4%

33%

26%

14%

Non-GAAP

Year-to-Date

Year-to-Date

(in millions)

2013

2012

2013

2012

Revenue

Amount

$

75,673

$

80,788

Growth rate

(6)%

6%

Operating earnings

Amount

$

1,439

$

1,388

$

1,574

$

1,441

Growth rate

4%

20%

9%

14%

Earnings from continuing operations

Amount

$

921

$

834

$

1,010

$

864

Growth rate

10%

10%

17%

12%

Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances.

Schedule 6

Cardinal Health, Inc. and Subsidiaries Segment Business Analysis

Third Quarter

Third Quarter

(in millions)

2013

2012

(in millions)

2013

2012

Pharmaceutical

Medical

Revenue

Revenue

Amount

$

22,070

$

24,508

Amount

$

2,484

$

2,414

Growth rate

(10)%

3%

Growth rate

3%

8%

Mix

90%

91%

Mix

10%

9%

Segment profit

Segment profit

Amount

$

498

$

446

Amount

$

100

$

89

Growth rate

12%

9%

Growth rate

12%

(17)%

Mix

83%

83%

Mix

17%

17%

Segment profit margin

2.26%

1.82%

Segment profit margin

4.01%

3.70%

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the three months ended March 31, 2013 was $24,552 million, which included total segment revenue of $24,554 million and Corporate revenue of $(2) million. Total consolidated revenue for the three months ended March 31, 2012 was $26,918 million, which included total segment revenue of $26,922 million and Corporate revenue of $(4) million.  Corporate revenue consists primarily of elimination of inter-segment revenue.

Total consolidated operating earnings for the three months ended March 31, 2013 were $475 million, which included total segment profit of $598 million and Corporate costs of $(123) million. Total consolidated operating earnings for the three months ended March 31, 2012 were $527 million, which included total segment profit of $535 million and Corporate costs of $(8) million. Corporate includes, among other things, restructuring and employee severance, acquisition-related costs, impairments and loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments. As noted on Schedule 7, of the $8 million adjustment recorded in the Medical segment during fiscal 2013 related to certain vendor chargeback billings, $4 million related to the third quarter of fiscal 2012.

Schedule 7

Cardinal Health, Inc. and Subsidiaries Segment Business Analysis

Year-to-Date

Year-to-Date

(in millions)

2013

2012

(in millions)

2013

2012

Pharmaceutical

Medical

Revenue

Revenue

Amount

$

68,314

$

73,591

Amount

$

7,363

$

7,210

Growth rate

(7)%

6%

Growth rate

2%

9%

Mix

90%

91%

Mix

10%

9%

Segment profit

Segment profit

Amount

$

1,339

$

1,204

Amount

$

268

$

253

Growth rate

11%

18%

Growth rate

6%

(14)%

Mix

83%

83%

Mix

17%

17%

Segment profit margin

1.96%

1.64%

Segment profit margin

3.63%

3.51%

Refer to definitions for an explanation of calculations.

Total consolidated revenue for the nine months ended March 31, 2013 was $75,673 million, which included total segment revenue of $75,677 million and Corporate revenue of $(4) million. Total consolidated revenue for the nine months ended March 31, 2012 was $80,788 million, which included total segment revenue of $80,801 million and Corporate revenue of $(13) million.  Corporate revenue consists primarily of elimination of inter-segment revenue.

Total consolidated operating earnings for the nine months ended March 31, 2013 were $1,439 million, which included total segment profit of $1,607 million and Corporate costs of $(168) million. Total consolidated operating earnings for the nine months ended March 31, 2012 were $1,388 million, which included total segment profit of $1,457 million and Corporate costs of $(69) million. Corporate includes, among other things, restructuring and employee severance, acquisition-related costs, impairments and loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments. Medical segment profit for fiscal 2013 includes an $8 million favorable out-of-period adjustment to reflect certain vendor chargeback billings that were delayed when we implemented our medical business transformation. Of the $8 million adjustment recorded during fiscal 2013, $4 million related to the third quarter of fiscal 2012.

Schedule 8

Cardinal Health, Inc. and Subsidiaries Schedule of Notable Items

Third Quarter

Year-to-Date

(in millions, except per Common Share amounts)

2013

2012

2013

2012

Restructuring and employee severance

$

(33)

$

(7)

$

(39)

$

(12)

Tax benefit

12

3

15

4

Restructuring and employee severance, net of tax

$

(21)

$

(4)

$

(24)

$

(8)

Decrease to diluted EPS from continuing operations

$

(0.06)

$

(0.01)

$

(0.07)

$

(0.02)

Acquisition-Related Costs

Amortization of acquisition-related intangible assets

$

(26)

$

(20)

$

(69)

$

(58)

Tax benefit

10

7

25

21

Amortization of acquisition-related intangible assets, net of tax

$

(16)

$

(13)

$

(44)

$

(37)

Decrease to diluted EPS from continuing operations

$

(0.05)

$

(0.04)

$

(0.13)

$

(0.11)

Other acquisition-related costs1

$

(26)

$

47

$

(37)

$

35

Tax benefit/(expense)1

10

(14)

13

(10)

Other acquisition-related costs, net of tax

$

(16)

$

33

$

(24)

$

25

Increase/(decrease) to diluted EPS from continuing operations1

$

(0.05)

$

0.10

$

(0.07)

$

0.07

Total acquisition-related costs2

$

(53)

$

27

$

(106)

$

(23)

Tax benefit/(expense)

20

(7)

38

11

Total acquisition-related costs, net of tax2

$

(33)

$

20

$

(68)

$

(12)

Increase/(decrease) to diluted EPS from continuing operations2

$

(0.10)

$

0.06

$

(0.20)

$

(0.03)

Impairments and loss on disposal of assets

$

(21)

$

(17)

$

(27)

$

(19)

Tax benefit

6

7

7

7

Impairments and loss on disposal of assets, net of tax

$

(15)

$

(10)

$

(20)

$

(12)

Decrease to diluted EPS from continuing operations

$

(0.04)

$

(0.03)

$

(0.06)

$

(0.03)

Litigation recoveries/(charges), net

$

3

$

$

37

$

3

Tax expense

(1)

(14)

(1)

Litigation recoveries/(charges), net, net of tax

$

2

$

$

23

$

2

Increase to diluted EPS from continuing operations

$

$

$

0.06

$

0.01

Other Spin-Off Costs

$

$

(1)

$

$

(2)

Tax benefit

1

Other Spin-Off Costs, net of tax

$

$

(1)

$

$

(1)

Decrease to diluted EPS from continuing operations

$

$

$

$

Weighted-average number of diluted shares outstanding

345

349

344

349

1           Includes a $55 million decrease in the fair value of the total contingent consideration obligation related to the P4 Healthcare acquisition for the three months ended March 31, 2012. The related tax expense was $20 million and diluted EPS from continuing operations increased $0.10.

2           The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Schedule 9

Cardinal Health, Inc. and Subsidiaries Asset Management Analysis

Third Quarter

Year-to-Date

2013

2012

2013

2012

Days sales outstanding1

23.5

21.7

Days inventory on hand

27.5

25.0

Days payable outstanding

39.8

38.3

Net working capital days2

11.2

8.5

Debt to total capital

38

%

29

%

Net debt to capital

21

%

2

%

Return on equity

20.7

%

21.9

%

18.9

%

18.7

%

Non-GAAP return on equity

24.7

%

21.6

%

20.8

%

19.4

%

Effective tax rate from continuing operations3

22.7

%

34.9

%

32.7

%

36.9

%

Non-GAAP effective tax rate from continuing operations3

25.1

%

35.6

%

32.8

%

37.1

%

1           We changed our method of calculating days sales outstanding and have revised prior-year information to conform, refer to Schedule 14.

2       The sum of the components may not equal the total due to rounding.

3       The revaluation of the deferred tax liability and related interest on unrepatriated foreign earnings as a result of an agreement with tax authorities reduced, for fiscal 2013 third quarter, both the effective tax rate from continuing operations and non-GAAP effective tax rate from continuing operations by 14.2 and 11.6 percentage points, respectively. The fiscal 2013 third quarter non-GAAP effective tax rate from continuing operations, excluding the impact of the tax settlement, would have been 36.7%.

Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances. Refer to DSO, DIOH and DPO for definitions and calculations.

Schedule 10

Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation

Third Quarter 2013

Operating

Earnings Before

Provision

Earnings

Earnings from

Diluted EPS

Diluted EPS

Earnings

Income Taxes

for

from

Continuing

from

from Continuing

Operating

Growth

and Discontinued

Income

Continuing

Operations

Continuing

Operations

(in millions, except per Common Share amounts)

Earnings

Rate

Operations

Taxes

Operations

Growth Rate

Operations

Growth Rate

GAAP

$

475

(10)

%

$

447

$

101

$

346

4

%

$

1.00

5

%

Restructuring and employee severance

33

33

12

21

0.06

Acquisition-related costs

53

53

20

33

0.10

Impairments and loss on disposal of assets

21

21

6

15

0.04

Litigation (recoveries)/charges, net

(3)

(3)

(1)

(2)

Other Spin-Off Costs

Non-GAAP

$

579

11

%

$

551

$

138

$

412

26

%

$

1.20

28

%

Third Quarter 2012

GAAP

$

527

18

%

$

510

$

178

$

332

33

%

$

0.95

34

%

Restructuring and employee severance

7

7

3

4

0.01

Acquisition-related costs

(27)

(27)

(7)

(20)

(0.06)

Impairments and loss on disposal of assets

17

17

7

10

0.03

Litigation (recoveries)/charges, net

Other Spin-Off Costs

1

1

1

Non-GAAP

$

524

6

%

$

508

$

181

$

327

14

%

$

0.94

16

%

Year-to-Date 2013

Operating

Earnings Before

Provision

Earnings

Earnings from

Diluted EPS

Diluted EPS

Earnings

Income Taxes

for

from

Continuing

from

from Continuing

Operating

Growth

and Discontinued

Income

Continuing

Operations

Continuing

Operations

(in millions, except per Common Share amounts)

Earnings

Rate

Operations

Taxes

Operations

Growth Rate

Operations

Growth Rate

GAAP

$

1,439

4

%

$

1,369

$

448

$

921

10

%

$

2.68

12

%

Restructuring and employee severance

39

39

15

24

0.07

Acquisition-related costs

106

106

38

68

0.20

Impairments and loss on disposal of assets

27

27

7

20

0.06

Litigation (recoveries)/charges, net

(37)

(37)

(14)

(23)

(0.06)

Other Spin-Off Costs

Non-GAAP

$

1,574

9

%

$

1,504

$

494

$

1,010

17

%

$

2.94

19

%

Year-to-Date 2012

GAAP

$

1,388

20

%

$

1,321

$

487

$

834

10

%

$

2.39

11

%

Restructuring and employee severance

12

12

4

8

0.02

Acquisition-related costs

23

23

11

12

0.03

Impairments and loss on disposal of assets

19

19

7

12

0.03

Litigation (recoveries)/charges, net

(3)

(3)

(1)

(2)

(0.01)

Other Spin-Off Costs

2

2

1

1

Non-GAAP

$

1,441

14

%

$

1,374

$

509

$

864

12

%

$

2.47

12

%

The sum of the components may not equal the total due to rounding.

We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Schedule 11

Cardinal Health, Inc. and Subsidiaries GAAP / Non-GAAP Reconciliation

Third Quarter

(in millions)

2013

2012

GAAP return on equity

20.7

%

21.9

%

Non-GAAP return on equity

Net earnings

$

345

$

333

Restructuring and employee severance, net of tax, in continuing operations

21

4

Acquisition-related costs, net of tax, in continuing operations

33

(20)

Impairments and loss on disposal of assets, net of tax, in continuing operations

15

10

Litigation (recoveries)/charges, net, net of tax, in continuing operations

(2)

Other Spin-Off Costs, net of tax, in continuing operations

1

Adjusted net earnings

$

412

$

328

Annualized

$

1,648

$

1,312

Third

Second

Third

Second

Quarter

Quarter

Quarter

Quarter

2013

2013

2012

2012

Total shareholders' equity

$

6,830

$

6,542

$

6,240

$

5,928

Divided by average shareholders' equity

$

6,686

$

6,084

Non-GAAP return on equity

24.7

%

21.6

%